Last reviewed · How we verify
ALKS 9072, Low
ALKS 9072 is a mu opioid receptor partial agonist designed to treat opioid use disorder by reducing cravings and withdrawal symptoms.
ALKS 9072 is a mu opioid receptor partial agonist designed to treat opioid use disorder by reducing cravings and withdrawal symptoms. Used for Opioid use disorder.
At a glance
| Generic name | ALKS 9072, Low |
|---|---|
| Sponsor | Alkermes, Inc. |
| Drug class | Mu opioid receptor partial agonist |
| Target | Mu opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Addiction Medicine |
| Phase | Phase 3 |
Mechanism of action
ALKS 9072 binds to mu opioid receptors with partial agonist activity, providing sufficient receptor stimulation to prevent withdrawal and reduce drug-seeking behavior while maintaining a ceiling effect that limits euphoria and overdose risk. This mechanism is similar to buprenorphine but represents a distinct molecular entity being developed by Alkermes for opioid use disorder treatment.
Approved indications
- Opioid use disorder
Common side effects
- Nausea
- Headache
- Constipation
- Withdrawal symptoms
Key clinical trials
- A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) (PHASE3)
- A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia (PHASE1)
- An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALKS 9072, Low CI brief — competitive landscape report
- ALKS 9072, Low updates RSS · CI watch RSS
- Alkermes, Inc. portfolio CI